This page has only limited features, please log in for full access.

Unclaimed
Maximilian Paul Postel
Department of Surgery, Campus Virchow-Klinikum and Campus Charité Mitte, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany

Basic Info

Basic Info is private.

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Journal article
Published: 28 July 2021 in Medicina
Reads 0
Downloads 0

Background and Objectives: Development of hepatitis-B is considered a serious complication after liver transplantation. HBV de novo infection is a rather rare phenomenon, however it deserves attention in the era of donor organ shortage. The aim of the present analysis was to examine its course in liver transplant patients. Materials and Methods: Prevalence of de novo HBV-infections was extracted from our local transplant data base. Analysis focused on the moment of HBV-detection and on the long-term follow-up in terms of biochemical and histological changes over 30 years. Results: 46 patients were identified with the diagnosis of de novo hepatitis B. Median time from liver transplantation to diagnosis was 397 days (7–5505). 39 patients received antiviral therapy. No fibrosis progression could be detected, whereas the grade of inflammation significantly lessened from the moment of HBV detection to the end of histological follow-up over a median of 4344 days (range 123–9490). Patients with a poor virological control demonstrated a significantly poorer overall survival. Conclusions: De novo hepatitis B in liver transplant patients is a condition that can be controlled very well without significant fibrosis progression or graft loss if recognized on time within a regular transplant follow-up schedule.

ACS Style

Ramin Raul Ossami Saidy; Franziska Eurich; Maximilian Paul Postel; Eva Maria Dobrindt; Jasper Feldkamp; Selina Johanna Schaper; Johann Pratschke; Brigitta Globke; Dennis Eurich. Clinical and Histological Long-Term Follow-Up of De Novo HBV-Infection after Liver Transplantation. Medicina 2021, 57, 767 .

AMA Style

Ramin Raul Ossami Saidy, Franziska Eurich, Maximilian Paul Postel, Eva Maria Dobrindt, Jasper Feldkamp, Selina Johanna Schaper, Johann Pratschke, Brigitta Globke, Dennis Eurich. Clinical and Histological Long-Term Follow-Up of De Novo HBV-Infection after Liver Transplantation. Medicina. 2021; 57 (8):767.

Chicago/Turabian Style

Ramin Raul Ossami Saidy; Franziska Eurich; Maximilian Paul Postel; Eva Maria Dobrindt; Jasper Feldkamp; Selina Johanna Schaper; Johann Pratschke; Brigitta Globke; Dennis Eurich. 2021. "Clinical and Histological Long-Term Follow-Up of De Novo HBV-Infection after Liver Transplantation." Medicina 57, no. 8: 767.

Journal article
Published: 13 May 2021 in Viruses
Reads 0
Downloads 0

Patients after LT due to combined HBV/HDV infection are considered to be high-risk patients for recurrence of hepatitis B and D. To date, life-long prophylaxis with hepatitis B immunoglobulin (HBIG) and replication control with nucleos(t)ide analogs (NA) remains standard. We examined the course of 36 patients that underwent liver transplantation from 1989 to 2020 for combined HBV/HDV-associated end-stage liver disease in this retrospective study. Seventeen patients eventually discontinued HBIG therapy for various reasons. Their graft function, histopathological findings from routine liver biopsies and overall survival were compared with those that received an unaltered NA-based standard regimen combined with HBIG. The median follow-up was 204 and 227 months, respectively. The recurrence of HBV was 25% and did not differ between the groups of standard reinfection prophylaxis NA/HBIG (21.1%) and HBIG discontinuation (29.4%); (p = 0.56). No significant differences were found regarding the clinical course or histopathological aspects of liver tissue damage (inflammation, fibrosis, steatosis) between these two groups. Overall, and adjusted survival did not differ between the groups. Discontinuation of HBIG in stable patients after LT for combined HBV/HDV did not lead to impaired overall survival or higher recurrence rate of HBV/HDV infection in this long-term follow-up. Therefore, the recommendation of the duration of HBG administration must be questioned. The earliest time of discontinuation remains unclear.

ACS Style

Ramin Ossami Saidy; Irina Sud; Franziska Eurich; Mustafa Aydin; Maximilian Postel; Eva Dobrindt; Johann Pratschke; Dennis Eurich. Discontinuation of Passive Immunization Is Safe after Liver Transplantation for Combined HBV/HDV Infection. Viruses 2021, 13, 904 .

AMA Style

Ramin Ossami Saidy, Irina Sud, Franziska Eurich, Mustafa Aydin, Maximilian Postel, Eva Dobrindt, Johann Pratschke, Dennis Eurich. Discontinuation of Passive Immunization Is Safe after Liver Transplantation for Combined HBV/HDV Infection. Viruses. 2021; 13 (5):904.

Chicago/Turabian Style

Ramin Ossami Saidy; Irina Sud; Franziska Eurich; Mustafa Aydin; Maximilian Postel; Eva Dobrindt; Johann Pratschke; Dennis Eurich. 2021. "Discontinuation of Passive Immunization Is Safe after Liver Transplantation for Combined HBV/HDV Infection." Viruses 13, no. 5: 904.

Journal article
Published: 31 March 2021 in Cancers
Reads 0
Downloads 0

Introduction: Recurrence of hepatocellular carcinoma (rHCC) after liver transplantation (LT) is associated with limited survival. Therefore, identification of factors that prolong survival in these patients is of great interest. Surgical resection, radiotherapy, and transarterial chemoembolization (TACE) are established interventions to improve outcomes in these patients; however, the impact of immunosuppression is unknown. Methods: All patients diagnosed with rHCC in the follow-up after LT were identified from a database of liver recipients transplanted between 1988 and 2019 at our institution (Charité Universitätsmedizin Berlin, Germany). Based on the immunosuppressive regimen following diagnosis of rHCC and the oncological treatment approach, survival analysis was performed. Results: Among 484 patients transplanted for HCC, 112 (23.1%) developed rHCC in the follow-up. Recurrent HCC was diagnosed at a median interval of 16.0 months (range 1.0–203.0), with the majority presenting early after transplantation (63.0%, <2 years). Median survival after rHCC diagnosis was 10.6 months (0.3–228.7). Reduction of immunosuppression was associated with improved survival, particularly in patients with palliative treatment (8.4 versus 3.0 months). In addition, greater reduction of immunosuppression seemed to be associated with greater prolongation of survival. Graft rejection after reduction was uncommon (n = 7, 6.8%) and did not result in any graft loss. Patients that underwent surgical resection showed improved survival rates (median 19.5 vs. 8.7 months). Conclusion: Reduction of immunosuppressive therapy after rHCC diagnosis is associated with prolonged survival in LT patients. Therefore, reduction of immunosuppression should be an early intervention following diagnosis. In addition, surgical resection should be attempted, if technically feasible and oncologically meaningful.

ACS Style

Ramin Ossami Saidy; Maximilian Postel; Michael Pflüger; Wenzel Schoening; Robert Öllinger; Safak Gül-Klein; Moritz Schmelzle; Frank Tacke; Johann Pratschke; Dennis Eurich. Minimization of Immunosuppressive Therapy Is Associated with Improved Survival of Liver Transplant Patients with Recurrent Hepatocellular Carcinoma. Cancers 2021, 13, 1617 .

AMA Style

Ramin Ossami Saidy, Maximilian Postel, Michael Pflüger, Wenzel Schoening, Robert Öllinger, Safak Gül-Klein, Moritz Schmelzle, Frank Tacke, Johann Pratschke, Dennis Eurich. Minimization of Immunosuppressive Therapy Is Associated with Improved Survival of Liver Transplant Patients with Recurrent Hepatocellular Carcinoma. Cancers. 2021; 13 (7):1617.

Chicago/Turabian Style

Ramin Ossami Saidy; Maximilian Postel; Michael Pflüger; Wenzel Schoening; Robert Öllinger; Safak Gül-Klein; Moritz Schmelzle; Frank Tacke; Johann Pratschke; Dennis Eurich. 2021. "Minimization of Immunosuppressive Therapy Is Associated with Improved Survival of Liver Transplant Patients with Recurrent Hepatocellular Carcinoma." Cancers 13, no. 7: 1617.